Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Joanne Chen Joanne Chen is an editor on the home-decor team. She edits ...

Participants treated with Descartes-08 were observed to have an average Quantitative Myasthenia Gravis Score (QMG) reduction of 4.8 (±1.7) points at month 4, which deepened through month 12 (6.0 ...

The FDA is reviewing a request for approval of FcRn blocker nipocalimab in generalized myasthenia gravis (gMG). J&J is late to the party, with argenx and UCB already selling rival FcRn blockers ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 ...

anti-LRP4+) adults with generalised myasthenia gravis (gMG). 1, 2 Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL b and QMG c scores over 84 weeks ...

1 Antozzi, C et al., Long-Term Safety and Efficacy of Nipocalimab in Generalized Myasthenia Gravis: Vivacity-MG3 Open-Label Extension Phase Results. Abstract #022 for poster presentation at 2025 ...

Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. Current disease-modifying therapies for multiple ...